Add more subjects after a failed BE study of a HVD [Study As­sess­ment]

posted by wxp  – China, 2013-05-28 07:13 (4779 d 23:24 ago) – Posting: # 10668
Views: 16,559

❝ ... Translating statistics into simple words: You have already “consumed” the entire 5% in the first study and nothing is “left” for the add-on.

❝ Some remarks for the future:Always plan for the PK metric with the higher CV (in most cases Cmax)...


Thank you, Helmut, for your explanation and answers to my questions. I learnt a lot from the failed BE study. It is worth the time to make a deliberate plan (protocol) before the study.

❝ ... You would need a replicate design (preferably a full replicate: RTR|TRT or RTRT|TRTR). For the required sample sizes see sampleN.RSABE (FDA) and sampleN.scABEL (EMA).


I tried both with CV=0.68. 42 subjects are needed for EMA, while only 27 subjects are needed for FDA. We plan to redo the BE study with a RSABE or SCABEL design.

Learn from the failed study. Did you sample frequently enough in order to “catch” Cmax in all subjects? This is a very important aspect especially for delayed release formulations...


It was a BE study of an old drug's conventional tablet. We sampled frequently enough to "catch" the Cmax. :-)

Thanks a lot for the slides and references.

Best regards,

Xipei
China

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
317 visitors (0 registered, 317 guests [including 16 identified bots]).
Forum time: 06:37 CEST (Europe/Vienna)

Most scientists today are devoid of ideas, full of fear, intent on
producing some paltry result so that they can add to the flood
of inane papers that now constitutes “scientific progress”
in many areas.    Paul Feyerabend

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5